Jean-Paul Squifflet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jean-Paul Squifflet has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Jacques Malaise
EUROSPK Central Office, Brussels, Belgium
2 shared publications - Michel Mourad
Department of Surgery, Surgery and Abdominal Transplantation Division, Cliniques Universitaires St Luc, Brussels, Belgium
2 shared publications Alessandra Baldi
1 shared publicationAriane Desmyttere
1 shared publicationBonita Siegal
1 shared publicationChristophe Legendre
1 shared publication
Latest Publications
- 1 September 2006
- Vol. 16 (3) , 206-14
Nonadherence with immunosuppressive drugs: U.S. compared with European kidney transplant recipients.
System factors increasingly are suggested as important yet understudied correlates of nonadherence. To explore the relationship between healthcare system and prevalence of nonadherence with immunosuppressive regimen by studying variation in nonadherence between European and US kidney transplant recipients and as well as nonadherence in European countries. We performed a secondary data analysis on data collected in 3 independent cross-sectional studies using comparable methodology including patients from the United States, the Netherlands, Belgium, and Switzerland. Nonadherence was measured using 1 item of the Siegal questionnaire. Patients were categorized as nonadherent if they reported missing a dose of immunosuppression in the last 4 weeks. Analyses were performed by multiple mixed logistic regression, with center as a random effect and clinical and demographical differences between groups as fixed effects. 1563 U.S. and 614 European patients from 3 different countries (Belgium [n=187], the Netherlands [n=85], and Switzerland [n=342]) were included. Prevalence of nonadherence in the United States and Europe was 19.3% and 13.2.%, respectively. This higher nonadherence in US patients was confirmed in a multiple logistic regression analysis (OR = 1.78; 95% CI, 1.10-2.89). Nonadherence differed between Belgium (16%) and the Netherlands (14.1%) (OR = 0.27; 95% CI, 0.09-0.80) and between Belgium and Switzerland (11.4%; OR = 0.17; 95% CI, 0.0-0.42). This is the first study showing differences in prevalence of nonadherence between European and US patients and among European patients. Further research should aim at unraveling the dynamics explaining these differences.
- 1 September 2006
- Vol. 16 (3) , 206-14
Nonadherence with immunosuppressive drugs: U.S. compared with European kidney transplant recipients.
System factors increasingly are suggested as important yet understudied correlates of nonadherence. To explore the relationship between healthcare system and prevalence of nonadherence with immunosuppressive regimen by studying variation in nonadherence between European and US kidney transplant recipients and as well as nonadherence in European countries. We performed a secondary data analysis on data collected in 3 independent cross-sectional studies using comparable methodology including patients from the United States, the Netherlands, Belgium, and Switzerland. Nonadherence was measured using 1 item of the Siegal questionnaire. Patients were categorized as nonadherent if they reported missing a dose of immunosuppression in the last 4 weeks. Analyses were performed by multiple mixed logistic regression, with center as a random effect and clinical and demographical differences between groups as fixed effects. 1563 U.S. and 614 European patients from 3 different countries (Belgium [n=187], the Netherlands [n=85], and Switzerland [n=342]) were included. Prevalence of nonadherence in the United States and Europe was 19.3% and 13.2.%, respectively. This higher nonadherence in US patients was confirmed in a multiple logistic regression analysis (OR = 1.78; 95% CI, 1.10-2.89). Nonadherence differed between Belgium (16%) and the Netherlands (14.1%) (OR = 0.27; 95% CI, 0.09-0.80) and between Belgium and Switzerland (11.4%; OR = 0.17; 95% CI, 0.0-0.42). This is the first study showing differences in prevalence of nonadherence between European and US patients and among European patients. Further research should aim at unraveling the dynamics explaining these differences.
- 26 January 2004
- Published by Elsevier in Transplantation Proceedings
- Vol. 36 (2) , S352-S355
The use of cyclosporine in renal and pancreas transplantation
- 26 January 2004
- Published by Elsevier in Transplantation Proceedings
- Vol. 36 (2) , S352-S355
The use of cyclosporine in renal and pancreas transplantation
- 13 August 2003
- Vol. 103, 10-20
The history of transplantation at the Catholic University of Louvain Belgium 1963-2003.
- 13 August 2003
- Vol. 103, 10-20
The history of transplantation at the Catholic University of Louvain Belgium 1963-2003.
- 1 January 2003
- Published by Taylor & Francis in Acta Chirurgica Belgica
- Vol. 103 (2) , 120-123
The Medical Responsibility: Current View from the Council of Physicians Side
The medical responsibility has been clearly defined in the Royal Decree n° 78 dated November 11,1967 concerning the medical practice. Moreover, several articles from the Ethical Code (Code de Déontologie) have clarified some social and economical responsibilities in the medical practice (articles 99 to 103) and the quality of patient care (article 36). The National Council has also published at least 31 advises facing the daily reality and the growing insecurity. That atmosphere is coming from the jurisprudence, the increasing responsibility insurance fees, the obligation of results instead of means, and the project of patient rights law. That project is currently dissociated from other projects such as an update on the medical responsibility and/or the no fault indemnity. Therefore, there is a current need for developing written patient information and using informed consent forms for risky surgical procedures. Before recognizing the no fault concept with indemnity, it is necessary to review the coverage of the responsibility insurance, educate the medical doctors in the no fault concept, study the mode of compensation for therapeutic hazards and differentiate the objective and subjective parts of the patient’s chart.
- 1 January 2003
- Published by Taylor & Francis in Acta Chirurgica Belgica
- Vol. 103 (2) , 120-123
The Medical Responsibility: Current View from the Council of Physicians Side
The medical responsibility has been clearly defined in the Royal Decree n° 78 dated November 11,1967 concerning the medical practice. Moreover, several articles from the Ethical Code (Code de Déontologie) have clarified some social and economical responsibilities in the medical practice (articles 99 to 103) and the quality of patient care (article 36). The National Council has also published at least 31 advises facing the daily reality and the growing insecurity. That atmosphere is coming from the jurisprudence, the increasing responsibility insurance fees, the obligation of results instead of means, and the project of patient rights law. That project is currently dissociated from other projects such as an update on the medical responsibility and/or the no fault indemnity. Therefore, there is a current need for developing written patient information and using informed consent forms for risky surgical procedures. Before recognizing the no fault concept with indemnity, it is necessary to review the coverage of the responsibility insurance, educate the medical doctors in the no fault concept, study the mode of compensation for therapeutic hazards and differentiate the objective and subjective parts of the patient’s chart.
- 1 January 2003
- Published by Taylor & Francis in Acta Chirurgica Belgica
- Vol. 103 (sup1) , 6-9
From Leg Transplantation by St Cosmas and St Damian to the Modern Era
(2003). From Leg Transplantation by St Cosmas and St Damian to the Modern Era. Acta Chirurgica Belgica: Vol. 103, The History of Organ Transplantation in Belgium. 4th Belgian Surgical Week, Oostende, May 1-3, 2003. Fortieth Annivesary of the First Human Cadaver Allograft (June 1963 - May 2003), pp. 6-9.
- 1 January 2003
- Published by Taylor & Francis in Acta Chirurgica Belgica
- Vol. 103 (sup1) , 6-9
From Leg Transplantation by St Cosmas and St Damian to the Modern Era
(2003). From Leg Transplantation by St Cosmas and St Damian to the Modern Era. Acta Chirurgica Belgica: Vol. 103, The History of Organ Transplantation in Belgium. 4th Belgian Surgical Week, Oostende, May 1-3, 2003. Fortieth Annivesary of the First Human Cadaver Allograft (June 1963 - May 2003), pp. 6-9.
- 1 January 2003
- Published by Taylor & Francis in Acta Chirurgica Belgica
- Vol. 103 (sup1) , 10-20
The History of Transplantation at the Catholic University of Louvain-Belgium 1963-2003
(2003). The History of Transplantation at the Catholic University of Louvain-Belgium 1963-2003. Acta Chirurgica Belgica: Vol. 103, The History of Organ Transplantation in Belgium. 4th Belgian Surgical Week, Oostende, May 1-3, 2003. Fortieth Annivesary of the First Human Cadaver Allograft (June 1963 - May 2003), pp. 10-20.
- 1 January 2003
- Published by Taylor & Francis in Acta Chirurgica Belgica
- Vol. 103 (sup1) , 10-20
The History of Transplantation at the Catholic University of Louvain-Belgium 1963-2003
(2003). The History of Transplantation at the Catholic University of Louvain-Belgium 1963-2003. Acta Chirurgica Belgica: Vol. 103, The History of Organ Transplantation in Belgium. 4th Belgian Surgical Week, Oostende, May 1-3, 2003. Fortieth Annivesary of the First Human Cadaver Allograft (June 1963 - May 2003), pp. 10-20.
- 15 October 2002
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 186 (s1) , S116-S122
The Economic Value of Valacyclovir Prophylaxis in Transplantation
Cytomegalovirus (CMV) infection and disease, with its extensive direct and indirect consequences, adds considerably to the cost of patient management in both solid organ and bone marrow transplantation. Antiviral prophylaxis for CMV infection can offer cost advantages over preemptive therapy and "wait-and-treat" approaches. Valacyclovir has demonstrated efficacy for CMV prophylaxis in renal, heart, and bone marrow transplantation and is cost-effective when compared with placebo in renal transplant recipients at high risk of CMV infection. In reducing CMV infection and disease, valacyclovir prophylaxis appears to be associated with reductions in indirect effects of CMV (acute graft rejection, other opportunistic infections) and, if these effects are considered, the potential exists for even greater savings to be made with valacyclovir therapy. Benefits of valacyclovir in transplantation extend beyond CMV to other herpesviruses and may be increased in some clinical situations by prolonging prophylaxis beyond 3 months.
- 15 October 2002
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 186 (s1) , S116-S122
The Economic Value of Valacyclovir Prophylaxis in Transplantation
Cytomegalovirus (CMV) infection and disease, with its extensive direct and indirect consequences, adds considerably to the cost of patient management in both solid organ and bone marrow transplantation. Antiviral prophylaxis for CMV infection can offer cost advantages over preemptive therapy and "wait-and-treat" approaches. Valacyclovir has demonstrated efficacy for CMV prophylaxis in renal, heart, and bone marrow transplantation and is cost-effective when compared with placebo in renal transplant recipients at high risk of CMV infection. In reducing CMV infection and disease, valacyclovir prophylaxis appears to be associated with reductions in indirect effects of CMV (acute graft rejection, other opportunistic infections) and, if these effects are considered, the potential exists for even greater savings to be made with valacyclovir therapy. Benefits of valacyclovir in transplantation extend beyond CMV to other herpesviruses and may be increased in some clinical situations by prolonging prophylaxis beyond 3 months.
- 1 August 2002
- Published by Elsevier in Transplantation Proceedings
- Vol. 34 (5) , 1584-1586
Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study
- 1 August 2002
- Published by Elsevier in Transplantation Proceedings
- Vol. 34 (5) , 1584-1586
Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study
- Open Access
- 17 February 2000
- Published by Frontiers Media SA in Transplant International
- Vol. 13 (1) , 35-40
Laparoscopic and open live donor nephrectomy: a cost/benefit study
Recently, laparoscopic live‐donor nephrectomy has been developed in order to increase organ donation. In this study we compare and review the records of 10 donors operated by open extraperitoneal approach and of 10 donors operated by a laparoscopic transperitoneal approach (LSC). Results show less use of postoperative parenteral narcotics in the LSC group (109 mg vs 272 mg; P < 0.0005) than in the extraperitoneal group. Morbidity was similar in both groups. There was no difference in postoperative stay. Allograft kidney function was similar in both groups until 6 months after donation. The use of disposable laparoscopic material bears an extra cost of 900 US$. We can thus conclude that laparoscopic live‐donor nephrectomy is a safe procedure that significantly reduces postoperative pain, and is not detrimental to the allograft. The total cost of the laparoscopic procedure will be lower than that of the open approach if the length of postoperative stay is cut by 3 days.
- 17 February 2000
- Published by Frontiers Media SA in Transplant International
- Vol. 13 (1) , 35-40
Open AccessLaparoscopic and open live donor nephrectomy: a cost/benefit study
Recently, laparoscopic live‐donor nephrectomy has been developed in order to increase organ donation. In this study we compare and review the records of 10 donors operated by open extraperitoneal approach and of 10 donors operated by a laparoscopic transperitoneal approach (LSC). Results show less use of postoperative parenteral narcotics in the LSC group (109 mg vs 272 mg; P < 0.0005) than in the extraperitoneal group. Morbidity was similar in both groups. There was no difference in postoperative stay. Allograft kidney function was similar in both groups until 6 months after donation. The use of disposable laparoscopic material bears an extra cost of 900 US$. We can thus conclude that laparoscopic live‐donor nephrectomy is a safe procedure that significantly reduces postoperative pain, and is not detrimental to the allograft. The total cost of the laparoscopic procedure will be lower than that of the open approach if the length of postoperative stay is cut by 3 days.